Abstract
BackgroundProstate cancer screening is controversial because of uncertainty about its benefits and risks. The aim of this survey was to reveal preferences of men concerning prostate cancer screening and to test the effect of an informative video on these preferences.MethodsA stated preferences questionnaire was sent by e-mail to men aged 50–75 with no history of prostate cancer. Half of them were randomly assigned to view an informative video. A discrete choice model was established to reveal men’s preferences for six prostate cancer screening characteristics: mortality by prostate cancer, number of false positive and false negative results, number of overdiagnosis, out-of-pocket costs and recommended frequency.ResultsA population-based sample composed by 1024 men filled in the entire questionnaire. Each attribute gave the expected sign except for overdiagnosis. The video seemed to increase the intention to abstain from prostate cancer screening.ConclusionsThe participants attached greater importance to a decrease in the number of false negatives and a reduction in prostate cancer mortality than to other risks such as the number of false positives and overdiagnosis. Further research is needed to help men make an informed choice regarding screening.
Highlights
Prostate cancer screening is controversial because of uncertainty about its benefits and risks
Prostate cancer screening has been highly controversial within the medical community because of the
About 15% of the population declared feeling afraid that they may have cancer often or most of the time and 18.03% knew someone with prostate cancer
Summary
Prostate cancer screening is controversial because of uncertainty about its benefits and risks. The aim of this survey was to reveal preferences of men concerning prostate cancer screening and to test the effect of an informative video on these preferences. Cancer screening participation is dependent on how people assess the benefit-risk ratio. Prostate cancer screening has been highly controversial within the medical community because of the Prostate cancer screening consists of assaying prostate specific antigen (PSA) in the blood and a digital rectal examination. In France, the test is prescribed in most cases by general practitioners (GP). They may refer the patient to a urologist in the event of an abnormal test result.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
